

# **ENTPD1 Antibody (N-term) Blocking Peptide**

Synthetic peptide Catalog # BP9233a

## **Specification**

## **ENTPD1** Antibody (N-term) Blocking Peptide - Product Information

Primary Accession

P49961

# ENTPD1 Antibody (N-term) Blocking Peptide - Additional Information

Gene ID 953

### **Other Names**

Ectonucleoside triphosphate diphosphohydrolase 1, NTPDase 1, Ecto-ATP diphosphohydrolase 1, Ecto-ATPDase 1, Ecto-ATPDase 1, Ecto-ATPDase 1, Ecto-ATPDase 1, Ecto-ATPD1, CD39

### Target/Specificity

The synthetic peptide sequence used to generate the antibody <a href=/products/AP9233a>AP9233a</a> was selected from the N-term region of human ENTPD1. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

### **Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

#### Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

# **Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

# **ENTPD1** Antibody (N-term) Blocking Peptide - Protein Information

## Name ENTPD1 (HGNC:3363)

### **Function**

Catalyzes the hydrolysis of both di- and triphosphate nucleotides (NDPs and NTPs) and hydrolyze NTPs to nucleotide monophosphates (NMPs) in two distinct successive phosphate-releasing steps, with NDPs as intermediates and participates in the regulation of extracellular levels of nucleotides (PubMed:<a href="http://www.uniprot.org/citations/8955160" target="\_blank">8955160</a>, PubMed:<a href="http://www.uniprot.org/citations/8529670" target="\_blank">8955160</a>, PubMed:<a href="http://www.uniprot.org/citations/8996251" target="\_blank">8996251</a>, PubMed:<a href="http://www.uniprot.org/citations/8626624" target="\_blank">8996251</a>, PubMed:<a href="http://www.uniprot.org/citations/8626624" target="\_blank">8626624</a>) (Probable). By hydrolyzing proinflammatory ATP and platelet-activating ADP to AMP, it blocks platelet aggregation and supports blood flow (PubMed:<a href="http://www.uniprot.org/citations/8955160" target=" blank">8955160</a>, PubMed:<a href="http://www.uniprot.org/citations/8955160" target=" blank">8955160</a>, PubMed:<a



href="http://www.uniprot.org/citations/8996251" target=" blank">8996251</a>).

### **Cellular Location**

Membrane; Multi-pass membrane protein. Membrane, caveola

### **Tissue Location**

Expressed primarily on activated lymphoid cells (PubMed:7930580). Also expressed in endothelial tissues (PubMed:8955160). Highly expressed in placenta, lung, skeletal muscle, kidney (PubMed:8955160).

## **ENTPD1** Antibody (N-term) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

### • Blocking Peptides

**ENTPD1** Antibody (N-term) Blocking Peptide - Images

# ENTPD1 Antibody (N-term) Blocking Peptide - Background

In the nervous system, ENTPD1 could hydrolyze ATP and other nucleotides to regulate purinergic neurotransmission. ENTPD1 Could also be implicated in the prevention of platelet aggregation, Hydrolyzes ATP and ADP equally well.

# **ENTPD1** Antibody (N-term) Blocking Peptide - References

Spanevello, R.M., et.al., Clin. Chim. Acta 411 (3-4), 210-214 (2010) Ndhlovu, L.C., et.al, Eur. J. Immunol. 40 (1), 134-141 (2010)